- Home
- ACRS vs WALD Comparison
ACRS vs WALD Comparison
Compare ACRS & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | WALD |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 228.8M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACRS | WALD |
|---|---|---|
| Price | $3.06 | $1.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $9.75 | $4.76 |
| AVG Volume (30 Days) | ★ 1.2M | 174.0K |
| Earning Date | 11-06-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,742,000.00 | ★ $274,560,000.00 |
| Revenue This Year | N/A | $4.61 |
| Revenue Next Year | $6.06 | $11.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.22 |
| 52 Week Low | $1.05 | $1.48 |
| 52 Week High | $3.48 | $4.10 |
Technical Indicators
Market Signals| Indicator | ACRS | WALD |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 41.61 |
| Support Level | $3.12 | $1.77 |
| Resistance Level | $3.48 | $2.00 |
| Average True Range (ATR) | 0.22 | 0.17 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 52.54 | 24.72 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.